Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Systematic review and meta-analysis show lead in HbA1c reduction, weight loss, and favorable fasting blood glucose levels.
Read More »Study Shows Advantage of SGLT2’s Over DPP-4’s
Controversy Between SGLT-2 Inhibitors and GLP-1 Agonists as Preferred Second-Line Therapy
Patient specific considerations have to be taken into account prior to choosing GLP-1 agonist or SGLT2 inhibitor as second-line anti-hyperglycemic agent.
Read More »How Does Empagliflozin Reduce Cardiovascular Mortality In Type 2 Patients, Including Those With PAD?
The answer comes from a mediation analysis of the EMPA-REG OUTCOME Trial.
Read More »SGLT-2 Inhibitors Vs DPP-4 Inhibitors Vs. GLP1’s For Type 2 Diabetes
How best to decide whether to use one or a combination of the new treatments and individualize the treatment for your patients.
Read More »Are You Staying Informed With New Diabetes Treatments?
Poll finds less than half of health care professionals aware of newest drug up for FDA approval.
Read More »Efficacy And Safety When Adding Ertugliflozin to Metformin and Sitagliptin
New SGLT-2 inhibitor can be used as add-on therapy to provide better improvement in HbA1C in patients with type 2 diabetes.
Read More »Real-World Benefits for SGLT-2 Inhibitors
Patients with type 2 diabetes usually do not die from diabetes, but from cardiovascular disease and strokes.
Read More »New Information on SGLT-2 Inhibitors
Research presented at the American Heart Association provided new insight into two large diabetes drug trials, CANVAS and EMPA-REG OUTCOME.
Read More »Samuel Engel Part 1, Merck Vertis Met Studies
In part 1 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of the new SGLT-2, ertugliflozin.
Read More »More Acute Renal Failure Adverse Events With SGLT-2
SGLT-2 inhibitors were associated with more acute renal failure reports than other diabetes medications.
Read More »